By Christina Morales, Editor-in-Chief
Periscope News Group
June 27, 2018

According to an Order made by the U.S. District Court, Eastern District of Louisiana, the first trial concerning Taxotere and its link to permanent alopecia (hair loss) is scheduled for May 13th – 24th, 2019. Four other trials addressing this same issue also have set court dates: September 16-27, 2019, January 27-February 7, 2020, May 11-22, 2020, and September 14-25, 2020. This is a huge step forward for those who took Taxotere for breast cancer and were never warned about the possibility of never again having a full head of hair.

Taxotere (docetaxel) is a chemotherapy drug marketed by Sanofi-Aventis that was originally approved by the U.S. Food & Drug Administration (FDA) in 1996 to treat breast cancer. While many cancer patients are aware that hair loss is a common side effect of chemotherapy treatments, very few who took Taxotere were warned that their hair may come back in sparse patches or potentially not at all. Additionally, there were two other important pieces of information that were kept from these cancer patients who were given Taxotere: 1) there are other chemotherapy medications available that do not have the same risk as Taxotere, and yet patients weren’t told of their options and 2) the European medical community was informed of the potential for docetaxel related permanent hair loss in 2005 and the Canadian Taxotere label underwent a similar modification in 2012. However, the mention of the risk of permanent hair loss was not added to the U.S. label until 2015 (and it was buried on page 32 out of 64 pages!).

Currently there are more than 8,700 cases that have been centralized to the Eastern District of Louisiana, where all federally-filed hair loss claims against Taxotere and Docetaxel have been consolidated to review studies, claims, testimonies, and other pretrial proceedings. Bellwether trials serve as test cases and their verdicts are meant to be predictors as to how other juries could view similar Taxotere lawsuits.

If you experienced full or partial permanent hair loss after taking Taxotere and your chemotherapy treatments have been completed for six months or longer, you may be able to join the thousands of others who are making a claim against the makers of Taxotere or docetaxel. You weren’t warned that your hair may never return nor were you told that there are safer options. Fighting cancer is devastating enough without having to live the rest of your life with the struggles that are associated with permanent alopecia. Contact us today to see if you are eligible for financial compensation. Since court dates are set, time is short to make a claim and you deserve to be heard.


Further Information

For more information about Taxotere, click here now. For interviews or to tell your story, contact Jennifer Stanich-Banmiller at (925) 964-1485 or at info@periscopegroup.com.